Lanraplenib succinate is a highly selective, orally active SYK inhibitor with an IC50 of 9.5 nM. It targets SYK activity in platelets through the glycoprotein VI (GPVI) receptor, demonstrating potential therapeutic effects in inflammatory diseases. Notably, Lanraplenib succinate does not prolong bleeding time in preclinical models, indicating a favorable safety profile for clinical applications.
Lanraplenib succinate is a highly selective, orally active SYK inhibitor with an IC50 of 9.5 nM. It targets SYK activity in platelets through the glycoprotein VI (GPVI) receptor, demonstrating potential therapeutic effects in inflammatory diseases. Notably, Lanraplenib succinate does not prolong bleeding time in preclinical models, indicating a favorable safety profile for clinical applications.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
